Are Allergy Drops FDA Approved? The Off-Label Explainer

No. Off-label use is legal and common throughout medicine; many widely used treatments are prescribed off-label based on clinical evidence and professional judgment. Not being FDA-approved means the specific compounded product did not go through the FDA's formal approval process, not that it is illegal or inherently dangerous. Sublingual immunotherapy generally has a favorable safety profile, with most side effects being mild and local, such as mouth itching. That said, off-label status is a real distinction patients should understand: there isn't an FDA-reviewed label defining the product, and insurers generally don't cover the drops for this reason. A prescriber still evaluates your case, screens for contraindications, and oversees treatment, which is an important safeguard regardless of approval status.

FDA-approved SLIT tablets, such as Grastek, Oralair, Ragwitek, and Odactra, are standardized single-allergen drugs that completed clinical trials and FDA review. Allergy drops are compounded liquid extracts, often covering several allergens at once, that are personalized to the individual and used off-label. The tablets come in fixed doses and target one allergen group each, while drops are tailored to your specific sensitivities. Because tablets are approved drugs, they may be covered by insurance, whereas off-label liquid drops generally are not. The FDA approval of the tablets does not extend to drops, so it is inaccurate to call drops FDA-approved by association. They are genuinely different products serving overlapping but distinct purposes.

FDA approval is built around standardized products: a manufacturer runs controlled clinical trials on a single, consistently made product for a defined use, then submits the data for review. Custom allergy drops don't fit that model because they are compounded individually to match each patient's unique allergen profile, so there is no single fixed product to test and approve. The FDA has noted that compounded medications generally have not been FDA-approved. This is a structural mismatch rather than a verdict on the therapy itself; the broader category of sublingual immunotherapy has moderate-grade supporting evidence. It does mean, however, that drops remain off-label, which is why honest pages describe them that way instead of implying approval.

Generally, no. Because custom liquid allergy drops are used off-label and are not an FDA-approved product, private insurers, Medicare, and Medicaid typically do not cover the drops themselves. There is no approved product code to reimburse. In some cases, a billable clinical or visit component may be partially covered, but the compounded drops are usually an out-of-pocket cost. The good news is that allergy drops are commonly HSA- and FSA-eligible, so you may be able to pay with pre-tax dollars. FDA-approved SLIT tablets, being standard prescription drugs, are more likely to be covered. If coverage matters to you, it is worth confirming the specifics with both your insurer and the program before starting.

No, and this is a common misreading of what off-label means. Off-label refers to a specific compounded product not having gone through the FDA's formal approval process; it does not mean the underlying therapy is unstudied. Sublingual immunotherapy as a treatment category has a substantial research base: a large 2013 systematic review in JAMA evaluating dozens of randomized trials found moderate-grade evidence that SLIT reduces allergic rhinitis and rhinoconjunctivitis symptoms. The gap is structural, since personalized compounded extracts cannot easily be tested as a single standardized product, not a sign that the evidence is absent. Honest framing acknowledges both truths at once: the drops are not FDA-approved and are used off-label, and the broader sublingual immunotherapy approach is supported by moderate-grade clinical evidence, which is why prescribers can reasonably offer it.